<code id='9BE75A5E8C'></code><style id='9BE75A5E8C'></style>
    • <acronym id='9BE75A5E8C'></acronym>
      <center id='9BE75A5E8C'><center id='9BE75A5E8C'><tfoot id='9BE75A5E8C'></tfoot></center><abbr id='9BE75A5E8C'><dir id='9BE75A5E8C'><tfoot id='9BE75A5E8C'></tfoot><noframes id='9BE75A5E8C'>

    • <optgroup id='9BE75A5E8C'><strike id='9BE75A5E8C'><sup id='9BE75A5E8C'></sup></strike><code id='9BE75A5E8C'></code></optgroup>
        1. <b id='9BE75A5E8C'><label id='9BE75A5E8C'><select id='9BE75A5E8C'><dt id='9BE75A5E8C'><span id='9BE75A5E8C'></span></dt></select></label></b><u id='9BE75A5E8C'></u>
          <i id='9BE75A5E8C'><strike id='9BE75A5E8C'><tt id='9BE75A5E8C'><pre id='9BE75A5E8C'></pre></tt></strike></i>

          knowledge

          knowledge

          author:leisure time    Page View:43
          Medicare and money photo illustration.
          Adobe

          Medical technology lobby AdvaMed is fed up with the Centers for Medicare and Medicaid Services. In a letter sent to the agency and shared with STAT, the group urged CMS to act on finalizing a pathway that would make reimbursement for breakthrough devices easier. 

          CMS has been working on implementing the pathway since 2021. A CMS spokesperson told STAT the agency is working “expeditiously” to finalize it. Scott Whitaker, CEO of AdvaMed, said the device industry is tired of waiting.

          advertisement

          “I myself have begun to wonder if they’re really serious about doing this, or if they’re just saying they’re serious about doing it for political reasons or otherwise,” Whitaker told STAT. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          Longer MASH drug regimen improved liver, Akero study finds
          Longer MASH drug regimen improved liver, Akero study finds

          AdobeAkeroTherapeuticssaidMondaythatextendingtreatmentwithitsexperimentaldrugfortheliverdiseaseknown

          read more
          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more

          Harvard's David Sinclair gets blowback over aging

          DavidSinclairinhislabatHarvardMedicalSchool.CraigF.Walker/GlobeStaffRenownedHarvardUniversitygenetic